Peak Health Joins Hands with Jinhua Radio and Television to Organize Walking Activities
Release time:
2020-08-14
National Walking Bone Tailai Refueling
Peak Health Joins Jinhua Radio and Television to Organize Walking Activities
News from Our Country "Ah, I won the first prize, what is the prize?" on the morning of 10 March 20 , at Yongshengtang Store of Jianfeng Pharmacy, an aunt in a walking T-shirt held up a raffle ticket and excitedly asked the staff. On the morning of
10 and 20 and 21 , Jianfeng Health Technology Company, together with Jinhua Radio and Television Station, organized a demonstration and take-away activity of "All People Walking, Bone Tailai, Refueling". Nearly 200 walking enthusiasts took part in the activity.
This activity is divided into two routes, Jiangbei and Jiangnan. Each route has 9 clock-in points. The activity personnel wear unified sports T-shirts and sun hats to "exercise" with Jinhua Radio and Television host and peak health marketing team personnel ". During the brisk walk, Peak Health also set up a number of activities at clock-in points along the way. At punch-in point 3 , citizens can also make an appointment for a free bone density test. There is a question and answer on Gutai knowledge at punch-in point 5 , and participating citizens can get a gift. 7 punch-in point also set up a lucky draw. Citizens who reach the destination and finish playing cards in sequence can also receive a gift.
In addition, on the morning of 20 , a demonstration and departure ceremony was held in the main building of Jinhua Radio and Television Station. Chen Daiyou, general manager of Jianfeng Health, spoke on behalf of the enterprise. He hoped that everyone would strengthen exercise in their spare time, maintain a good physical and mental state, and better devote themselves to work and life.
Peak Health attracts citizens to participate in interaction through directional walking, integrates into the process of brand communication, and forms continuous attention through media promotion and public word of mouth, so that citizens can further understand the relevant knowledge of products while exercising their bodies, so as to achieve the purpose of publicity. At the same time, the free bone density measurement activities provided by Jianfeng Health allow the general public to understand their own bone health status, and they have also won unanimous praise from the citizens. (Zhang Ye Ni Yingzhen)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page